1. Home
  2. RYTM vs ACA Comparison

RYTM vs ACA Comparison

Compare RYTM & ACA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ACA
  • Stock Information
  • Founded
  • RYTM 2008
  • ACA 2018
  • Country
  • RYTM United States
  • ACA United States
  • Employees
  • RYTM N/A
  • ACA N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ACA Metal Fabrications
  • Sector
  • RYTM Health Care
  • ACA Industrials
  • Exchange
  • RYTM Nasdaq
  • ACA Nasdaq
  • Market Cap
  • RYTM 4.3B
  • ACA 4.8B
  • IPO Year
  • RYTM 2017
  • ACA N/A
  • Fundamental
  • Price
  • RYTM $61.99
  • ACA $84.76
  • Analyst Decision
  • RYTM Strong Buy
  • ACA Buy
  • Analyst Count
  • RYTM 12
  • ACA 3
  • Target Price
  • RYTM $76.75
  • ACA $104.00
  • AVG Volume (30 Days)
  • RYTM 525.0K
  • ACA 208.9K
  • Earning Date
  • RYTM 08-05-2025
  • ACA 07-31-2025
  • Dividend Yield
  • RYTM N/A
  • ACA 0.24%
  • EPS Growth
  • RYTM N/A
  • ACA N/A
  • EPS
  • RYTM N/A
  • ACA 1.59
  • Revenue
  • RYTM $136,863,000.00
  • ACA $2,603,300,000.00
  • Revenue This Year
  • RYTM $37.56
  • ACA $13.58
  • Revenue Next Year
  • RYTM $74.99
  • ACA $6.06
  • P/E Ratio
  • RYTM N/A
  • ACA $53.16
  • Revenue Growth
  • RYTM 48.88
  • ACA 10.44
  • 52 Week Low
  • RYTM $39.46
  • ACA $68.11
  • 52 Week High
  • RYTM $69.89
  • ACA $113.43
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 47.67
  • ACA 43.56
  • Support Level
  • RYTM $60.70
  • ACA $84.79
  • Resistance Level
  • RYTM $62.65
  • ACA $88.06
  • Average True Range (ATR)
  • RYTM 2.39
  • ACA 1.88
  • MACD
  • RYTM -0.52
  • ACA -0.54
  • Stochastic Oscillator
  • RYTM 14.04
  • ACA 6.43

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About ACA Arcosa Inc.

Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.

Share on Social Networks: